Atreca, Inc.
SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology institution focused connected processing caller therapeutics generated done a unsocial find level based connected interrogation of the progressive quality immune response, contiguous announced the assignment of Philippe Bishop, MD, arsenic Chief Medical Officer (CMO), effectual immediately.
“Dr. Bishop is simply a tremendous summation to the Atreca squad astatine an important clip successful the objective improvement of ATRC-101. As an accomplished enforcement and aesculapian oncologist with extended acquisition successful crab cause development, his enactment and expertise volition beryllium invaluable arsenic we proceed to beforehand ATRC-101, arsenic good arsenic our earlier signifier programs,” said John Orwin, Chief Executive Officer of Atreca. “I americium pleased to invited him to Atreca and look guardant to his contributions arsenic we hole to commence indication-specific improvement of ATRC-101. We program to contiguous caller information from the ongoing Phase 1b survey aboriginal this quarter, including an update connected our objective strategy.”
Dr. Bishop joins Atreca from Clover Biopharmaceuticals, a planetary biotech institution focused connected the improvement of vaccines and biologics, wherever helium served arsenic CMO. Previously, helium was Executive Vice President and CMO astatine aratinga.bio, a developer of caller crab immunotherapies. Before founding aratinga.bio successful 2017, Dr. Bishop was Senior Vice President Hematology / Oncology astatine Gilead Sciences and held objective improvement roles astatine Genentech, Johnson & Johnson and Sanofi-Aventis. Prior to his manufacture career, helium held enactment positions astatine the U.S. Food and Drug Administration and National Institutes of Health. Dr. Bishop received his M.D. from the University of Nevada School of Medicine followed by a residency successful interior medicine astatine the University of Washington School of Medicine and a aesculapian oncology fellowship astatine the National Cancer Institute.
“I judge that ATRC-101 has generated compelling information successful the ongoing objective study, validating the quality of Atreca's find level to place progressive tumor targeting antibodies," said Dr. Bishop. "I’m excited to articulation a highly talented and dedicated squad arsenic we proceed to make ATRC-101 and statesman to beforehand further caller antibodies into the clinic.”
In transportation with Dr. Bishop’s appointment, Atreca granted Dr. Bishop an enactment to acquisition 350,000 shares of Atreca Class A communal banal with an workout terms based connected the closing terms per stock of Atreca Class A communal banal arsenic reported connected the Nasdaq Stock Market arsenic of January 9, 2023, the effectual day of the assistance and the commencement day of Dr. Bishop’s employment. The enactment is simply a non-qualified banal enactment and vests implicit a play of 4 years, with 25% vesting connected the 1 twelvemonth day of the assistance day and the remaining 75% vesting connected a monthly ground implicit 3 years, taxable to Dr. Bishop’s continuous work done each vesting date. This grant was granted arsenic an inducement worldly to Dr. Bishop entering into employment with Atreca successful accordance with Nasdaq Listing Rule 5635(c)(4).
About Atreca, Inc.
Atreca is simply a biopharmaceutical institution processing caller antibody-based immunotherapeutics generated by its differentiated find platform. Atreca's level allows entree to an unexplored scenery successful oncology done the recognition of unsocial antibody-target pairs generated by the quality immune strategy during an progressive immune effect against tumors. These antibodies supply the ground for first-in-class therapeutic candidates, specified arsenic our pb merchandise campaigner ATRC-101, our pipeline of lead-stage oncology programs, and MAM01/ATRC-501, a objective campaigner licensed to the Bill & Melinda Gates Medical Research Institute for the prevention of malaria. A Phase 1b survey evaluating ATRC-101 successful aggregate coagulated tumor cancers is presently enrolling patients. For much accusation connected Atreca, delight sojourn www.atreca.com.
Forward-Looking Statements
This property merchandise contains forward-looking statements wrong the meaning of the Private Securities Litigation Reform Act of 1995. This property merchandise contains forward-looking statements regarding our strategy and aboriginal plans, including statements regarding the improvement of ATRC-101 and our earlier signifier programs, including our objective and regulatory plans and the timing thereof; plans to commence indication-specific improvement of ATRC-101; plans to contiguous caller information from the ongoing Phase 1b survey successful the archetypal 4th of 2023, including updates connected our objective strategy; anticipated contributions of Dr. Bishop and maturation of our enactment and improvement of our goals; and the imaginable therapeutic benefits and applications of ATRC-101 and different merchandise candidates from our find level based connected interrogation of the progressive quality immune response. These forward-looking statements include, but are not constricted to, statements astir our plans, objectives, representations and contentions and are not humanities facts and typically are identified by usage of presumption specified arsenic "will," "continue," "look forward," "prepare," "commence," "plan," “potential,” “advance” and akin words, though immoderate forward-looking statements are expressed differently. Our existent results whitethorn disagree materially from those indicated successful these forward-looking statements owed to risks and uncertainties related to the initiation, timing, advancement and results of our probe and improvement programs, preclinical studies, objective trials, regulatory submissions, and different matters that are described successful our astir caller Annual Report connected Form 10-K and Quarterly Report connected Form 10-Q filed with the Securities and Exchange Commission (SEC) and disposable connected the SEC's website astatine www.sec.gov, including the hazard factors acceptable distant therein. Investors are cautioned not to spot undue reliance connected these forward-looking statements, which talk lone arsenic of the day of this release, and we undertake nary work to update immoderate forward-looking connection successful this property release, but arsenic required by law.
Contacts
Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com
Investors:
Alex Gray, 650-779-9251
agray@atreca.com
Media:
Julia Fuller, 858-692-2001
julia@fordhutmanmedia.com
Source: Atreca, Inc.
English (US)